LON:MPH

Mereo BioPharma Group plc (MPH.L) Share Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
26.50
26.50
52-Week Range N/A
Volume49,264 shs
Average Volume333,975 shs
Market Capitalization£138.87 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone44 33 3023 7300
Employees50
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book ValueGBX 7.20 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap£138.87 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

See More Headlines
Mereo BioPharma Group plc (MPH.L) logo

About Mereo BioPharma Group plc (MPH.L)

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

MarketRank

Overall MarketRank

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mereo BioPharma Group plc (MPH.L) (LON:MPH) Frequently Asked Questions

What stocks does MarketBeat like better than Mereo BioPharma Group plc (MPH.L)?

Wall Street analysts have given Mereo BioPharma Group plc (MPH.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mereo BioPharma Group plc (MPH.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) released its quarterly earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share (EPS) for the quarter.
View Mereo BioPharma Group plc (MPH.L)'s earnings history
.

Who are Mereo BioPharma Group plc (MPH.L)'s key executives?

Mereo BioPharma Group plc (MPH.L)'s management team includes the following people:
  • Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 61, Pay $751.37k)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 51, Pay $545.68k)
  • Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 50, Pay $540.12k)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 63, Pay $512.99k)
  • Mr. Michael Stephen Wyzga MBA, Interim CFO & Exec. Director (Age 65, Pay $27.59k)
  • Ms. Alexandra Hughes-Wilson, Head of Patient Access & Commercial Planning (Age 49, Pay $265.93k)
  • Ms. Jill Henrich, US Site Head & Sr. VP of Regulatory Affairs (Age 57, Pay $286.93k)
  • Dr. John A. Lewicki, Chief Scientific Officer (Age 68)
  • Dr. Fiona Bor, Head of Intellectual Property
  • Mr. Ian Hodgson, Head of Clinical Operations

Who are some of Mereo BioPharma Group plc (MPH.L)'s key competitors?

What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA), Amgen (AMGN), ARMOUR Residential REIT (ARR), Arena Pharmaceuticals (ARNA) and Ardelyx (ARDX).

What is Mereo BioPharma Group plc (MPH.L)'s stock symbol?

Mereo BioPharma Group plc (MPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

How do I buy shares of Mereo BioPharma Group plc (MPH.L)?

Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

How much money does Mereo BioPharma Group plc (MPH.L) make?

Mereo BioPharma Group plc (MPH.L) has a market capitalization of £0.00.

How many employees does Mereo BioPharma Group plc (MPH.L) have?

Mereo BioPharma Group plc (MPH.L) employs 50 workers across the globe.

What is Mereo BioPharma Group plc (MPH.L)'s official website?

The official website for Mereo BioPharma Group plc (MPH.L) is mereobiopharma.com.

Where are Mereo BioPharma Group plc (MPH.L)'s headquarters?

Mereo BioPharma Group plc (MPH.L) is headquartered at 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom.

How can I contact Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L)'s mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The company can be reached via phone at 44 33 3023 7300.


This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.